Yesterday, for the first time, we presented the discovery, characterisation and chemical structure of our lead Targeted Glue™ AMX-883 during the ‘New Drugs on the Horizon’ session at #AACR26. More on AMX-883 and its potential to treat #AML patients here
https://
amphista.com/amphista-thera
peutics-presents-the-discovery-characterisation-and-chemical-structure-of-amx-883-an-orally-bioavailable-highly-potent-and-selective-dcaf16-degrader-of-brd9-at-aacr-2026/
…